Animal cells harbour multiple innate effector mechanisms that inhibit virus replication. For the pathogenic retrovirus human immunodeficiency virus type 1 (HIV-1), these include widely expressed restriction factors 1 , such as APOBEC3 proteins 2 , TRIM5a 3 , BST2 (refs 4, 5) and SAMHD1 (refs 6, 7) , as well as additional factors that are stimulated by type 1 interferon (IFN) [8] [9] [10] [11] [12] [13] [14] . Here we use both ectopic expression and gene-silencing experiments to define the human dynamin-like, IFN-induced myxovirus resistance 2 (MX2, also known as MXB) protein as a potent inhibitor of HIV-1 infection and as a key effector of IFN-a-mediated resistance to HIV-1 infection. MX2 suppresses infection by all HIV-1 strains tested, has equivalent or reduced effects on divergent simian immunodeficiency viruses, and does not inhibit other retroviruses such as murine leukaemia virus. The Capsid region of the viral Gag protein dictates susceptibility to MX2, and the block to infection occurs at a late post-entry step, with both the nuclear accumulation and chromosomal integration of nascent viral complementary DNA suppressed. Finally, human MX1 (also known as MXA), a closely related protein that has long been recognized as a broadly acting inhibitor of RNA and DNA viruses, including the orthomyxovirus influenza A virus 15, 16 , does not affect HIV-1, whereas MX2 is ineffective against influenza virus. MX2 is therefore a cell-autonomous, anti-HIV-1 resistance factor whose purposeful mobilization may represent a new therapeutic approach for the treatment of HIV/AIDS.
We reported previously that IFN-a pre-treatment of cultured human cells and cell lines establishes patterns of HIV-1 inhibition ranging from severe (monocyte-derived macrophages (MDMs), the monocytic line THP-1 and the glioblastoma line U87-MG), to intermediate (primary CD4 1 T cells), to minimal (lines such as CEM, HUT78 or Jurkat) 10, 17 . We therefore used transcriptional profiling of RNA isolated from 15 cultures (Jurkat, CEM, CEM-SS, HT1080, U87-MG, U937 6 phorbol 12-myristate 13-acetate (PMA), THP-1 6 PMA; MDMs from three donors; and CD4 1 T cells from three donors) in the presence or absence of IFN-a to identify candidate IFN-a-responsive, cell-encoded suppressors of HIV-1 infection (GEO accession number: GSE46599). Two selection criteria were applied to the data: (1) mean IFN-a-mediated induction of .fourfold across all samples; and (2) .fourfold higher expression in MDMs compared to CEM. Fourteen candidate genes were identified (Extended Data Table 1) , with CXCL10, STAT1 and OASL discounted from further study (the latter being cytotoxic). cDNAs for the remaining 11 genes were inserted into a doxycycline-inducible lentiviral vector, pEasiLV-MCS, in which transgene expression is repressed in vector-producing cells and transduction efficiency of target cells is scored by visualizing expression of E2-Crimson fluorescent protein ( Fig. 1a and Methods) .
As an initial screen for individual anti-viral capability, parental U87-MG CD4 1 CXCR4 1 cultures were untreated or treated with IFN-a, or transduced with high-titre stocks of each vector, as well as with negative control vectors expressing green fluorescent protein (GFP) or CD8, or a positive control expressing the TRIM5-cyclophilin A (TRIMCyp) fusion protein of owl monkeys, a well-established postentry inhibitor of HIV- 1 (ref. 18) . The cultures were induced with doxycycline and .85% of the cells in each culture were confirmed as E2-Crimson-positive (not shown). Five separate wells of each culture were then challenged with one of five escalating doses of HIV-1/ Nef-internal ribosome entry signal (IRES)-Renilla, a modified replication-competent virus, and productive infection quantified by monitoring activity of the Renilla luciferase reporter at 48 h ( Fig. 1b ). Only MX2 exhibited a clear anti-viral phenotype, with the levels of inhibition typically exceeding 90% and approaching those achieved with TRIMCyp or treatment with IFN-a. Similar results were obtained using vesicular stomatitis virus G-glycoprotein (VSV-G)-pseudotyped challenge virus, demonstrating that MX2-mediated inhibition occurs independently of the route of virus entry (Extended Data Fig. 1 ), as well as with CEM-SS and 293T target cells (Extended Data Fig. 2 ). The expression profile of MX2 in MDMs, primary T cells and cell lines was assessed by immunoblot ( Fig. 1c ) and quantitative PCR with reverse transcription (qRT-PCR) (Extended Data Fig. 3 ), confirming both IFN-a inducibility as well as preferential expression in cells displaying IFN-a-induced resistance to infection 10, 17 .
Having found that ectopic expression of MX2 is sufficient to confer resistance to HIV-1 infection, we used gene silencing to address the contribution of MX2 to the IFN-a-induced anti-viral state. U87-MG CD4 1 CXCR4 1 cells were transduced three to four times with either of two lentiviral vectors expressing MX2-specific short hairpin RNAs (shRNAs sh1 and sh2) or a non-targeting shRNA control vector. After at least 8 days, the cultures were incubated with or without IFN-a, challenged with HIV-1/Nef-IRES-Renilla, and infection monitored as Renilla luciferase activity ( Fig. 2a ). In cultures treated with IFN-a, MX2 silencing stimulated infection by five-to tenfold relative to the control, whereas no effect was noted in the absence of IFN-a, demonstrating that MX2 has a substantial role in the restriction of HIV-1 by IFN-a. Immunoblot analyses confirmed the efficiency of MX2 silencing (Fig. 2b, lanes 4 and 6) , and similar results were obtained in a second cell line, THP-1 (Extended Data Fig. 4 ).
Human MX2 is a member of the IFN-inducible guanosine triphosphatase (GTPase) superfamily that includes proteins involved in cellular processes requiring membrane remodelling, such as vesicular transport and cytokinesis, as well as in resistance to intracellular pathogens 19 . The most closely related family member is human MX1 (63% amino acid sequence identity), which inhibits a variety of RNA and DNA viruses, including influenza A virus, La Crosse encephalitis virus and hepatitis B virus, and is thought to form an oligomeric ring that engages and disrupts viral nucleoprotein/replication complexes 15, 20, 21 . Conversely, relatively little information concerning MX2 function is available: it is nuclear as well as cytoplasmic and accumulates at the cytoplasmic face of nuclear pore complexes. MX2 may have a role in cell cycle progression, but has not previously been ascribed notable anti-viral function 14, 16, 22, 23 .
To define more closely how MX2 inhibits HIV-1 replication, we challenged parental U87-MG CD4 1 CXCR4 1 cells, cultured with or without IFN-a, and cells transduced with CD8-or MX2-expressing vectors, with wild-type HIV-1 and then collected total DNA at 2, 6, 24 and 48 h. The 48-h cultures were also analysed for p24 Gag expression using flow cytometry, confirming MX2-mediated inhibition of viral gene expression (Extended Data Fig. 5 ). qPCR was then used to measure viral reverse transcripts representing three phases of replication: extended minus (first)-strand cDNA, 2-long terminal repeat (LTR) circular DNA (a marker for viral cDNA nuclear localization) and integrated (provirus) DNA ( Fig. 3 ). As reported previously, IFN-a treatment severely blocked the accumulation of all HIV-1 cDNAs 10 . By contrast, MX2 did not measurably affect the synthesis or accumulation of minus-strand cDNA, but reduced the levels of 2-LTR circles and proviruses by ,90%, possibly indicating a blockade to the nuclear uptake of viral replication complexes or a decrease in their stability.
We next examined the ability of MX2 to suppress infection by a range of primate lentiviruses including laboratory-adapted strains of HIV-1, HIV-1-transmitted founder strains, HIV-2 and simian immunodeficiency viruses (SIVs) derived from the rhesus macaque (SIV MAC ), mandrill (SIV MND ) or African green monkey (SIV AGM ). This was quantified by using the virus-encoded Tat proteins that are expressed after infection to trans-activate an HIV-LTR/luciferase reporter cassette that was resident in target U87-MG cells. These reporter cells were transduced with either CD8-or MX2-expressing vectors and subsequently challenged with two doses of VSV-Gpseudotyped stocks of HIVs or SIVs. Measurement of luciferase levels at 48 h showed that all HIV-1s and SIV MND were susceptible to potent repression by MX2, whereas HIV-2, SIV MAC and SIV AGM were somewhat less sensitive (Fig. 4a ). The analysis was then extended to three non-primate viruses, the lentiviruses equine infectious anaemia virus (EIAV) and feline immunodeficiency virus (FIV), and the gammaretrovirus murine leukaemia virus (MLV). Here, we used retroviral vectors encoding GFP and monitored single-cycle infectivity at 48 h by flow cytometry (Fig. 4b ). Interestingly, whereas MX2 suppressed infection by the HIV-1-based vector by ,80%, no inhibition of the three non-primate viruses was observed, demonstrating that the human MX2 protein exhibits substrate selectivity, albeit to differing extents, for primate lentiviruses.
Current views on the post-entry progression of HIV-1 infection invoke the sustained presence of the viral Capsid (CA) protein within reverse transcription complexes, as well as a central role for CA in mediating interactions with host proteins such as cyclophilin A, TNPO3, NUP358 (also known as RANBP2), NUP153 or TRIM5-a that influence the fate of infection 1,3,24-27 . To address whether CA 
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determines the sensitivity of HIV-1 to MX2, we measured the effects of MX2 using GFP-encoding vectors carrying the P90A or N74D mutations in CA that inhibit/prevent interactions with CypA, TNPO3, NUP358 or NUP153, or that had the CA region of Gag replaced with SIV MAC CA (Fig. 4c) . In contrast to the ,80% inhibition of wild-type Gag, the P90A and N74D CA variants were insensitive or only mildly sensitive to inhibition by MX2, respectively, and the SIV-CA-containing chimaera displayed modest inhibition, reflecting closely that of the parental SIV MAC protein. The observation that modifying HIV-1 CA can control MX2 susceptibility or escape suggests that CA is a specific target of MX2.
In a final series of experiments we assessed the effects of MX1 and MX2 on HIV-1 and influenza A virus replication (using analogous assays that measure the culmination of infection, viral RNA synthesis and protein expression). Influenza A virus genome segment replication was determined by co-transfecting 293T cells with a vector expressing a firefly luciferase-containing minigenome (as well as a vector expressing Renilla luciferase for normalization), together with vectors for wild-type MX1 or MX2 (Flag-tagged and -untagged), or the tagged GTPase-deficient MX1 derivatives K83A and T103A 28, 29 . At 24 h, the . Mean values of relative amounts of DNA (normalized to control at 48 h) from three independent experiments are shown. The detection limit for 2-LTR circle qPCR was ten copies per reaction, which corresponds to ,6% relative copies as indicated on the graph by a dashed grey line. p24 Gag expression was also determined at 48 h in parallel samples to monitor productive infection (Extended Data Fig. 5 ). 
Relative infection efficiency 
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cultures were infected with influenza A virus, and firefly luciferase expression measured 18 h later (Fig. 4d ). As established previously, wild-type MX1, as well as IFITM3 (positive control) 30 , suppressed replication by 75-80%, whereas the GTPase domain mutant proteins had lost anti-viral activity 28, 29 ; consistent with previous studies, MX2 did not exert any inhibitory effect 16 . The wild-type MX1 and MX2 proteins, and the K131A mutant of MX2 that does not bind GTP 22 , were then examined for their HIV-1 inhibitory phenotypes in transduced U87-MG CD4 1 CXCR4 1 cells as in Fig. 1b . In contrast to the results with influenza A virus, MX1 had no effect on HIV-1, and the mutated MX2(K131A) protein still retained a degree of anti-viral function (,65% inhibition, Fig. 4e ). Immunoblotting confirmed expression of the Flag-tagged proteins, although MX2(K131A) accumulated to a lower level than the wild-type protein (Extended Data Fig. 6 ).
Here we describe the identification of human MX2 as an IFN-ainducible anti-retroviral effector that, among primate immunodeficiency viruses, is most potent against HIV-1, but does not affect the non-primate viruses MLV, EIAV and FIV (Fig. 4a, b ). Understanding the molecular details of MX2's recognition and inactivation of post-entry viral reverse transcription complexes, the interplay with other regulatory host proteins that interact with CA, and the basis for the dichotomy between MX2/HIV-1 inhibition and MX1/influenza virus inhibition with respect to GTPase function ( Fig. 4d, e ) will help to elucidate the mechanism of this new mode of cell-mediated resistance to retroviral infection. As viral inhibition occurs relatively late during infection and is manifested as the failure to accumulate viral cDNA in the nucleus (Fig. 3) , the anti-viral action of MX2 is distinct from TRIM5-a-or APOBEC3Gmediated inhibition of early reverse transcription or SAMHD1-mediated restriction through deoxynucleotide triphosphate depletion 1 .
Last, we note that although MX2 silencing substantially relieves IFNa-induced resistance to HIV-1, measurable inhibition persists ( Fig. 2 and Extended Data Fig. 4) ; taken together with the observation that IFN-a imposes an early block to HIV-1 reverse transcription ( Fig. 3) 10 , we speculate that additional IFN-stimulated factor(s) that interfere with the initial post-entry phases of HIV-1 infection remain to be discovered.
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Plasmids, cells, viral vectors and EasiLV system. All reagents, including the novel inducible lentivirus vector pEasiLV-MCS, are described in Methods. Candidate cDNAs were cloned into pEasiLV-MCS for functional screening. Virus infection. Lentiviral, retroviral and influenza A virus infections were monitored using standard reporter genes, and HIV-1 cDNA was measured by qPCR. Microarray. Illumina HumanHT12v4 expression bead chips were probed with RNA from primary cells and cell lines, treated or not treated with IFN-a. MX2 silencing. MX2 silencing was achieved with shRNAs expressed from a lentiviral vector, generated using a modified version of pAPM, and primer sequences available on the Open Biosystems website (http://www.thermoscientificbio.com/ rnai-and-custom-rna-synthesis/shrna/gipz-lentiviral-shrna/) (target sequences: MX2-1, 59-AAGATGTTCTTTCTAATTG-39; MX2-2, 59-CCAACCAGATCCC ATTTAT-39).
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HIV-1, HIV-2 and SIV molecular clones, lentiviral and retroviral vectors.
HIV-1 proviral clones for the NL4-3, YU-2 and IIIB isolates have been described [31] [32] [33] . The NL4-3/Nef-IRES-Renilla reporter virus (which expresses Renilla luciferase from an internal ribosome entry site) was provided by S. Chanda and K. Olivieri, and the NL4-3/Nef-IRES-GFP reporter was obtained from the NIH AIDS Reagent and Reference Program (catalogue no. 11349, pBR43IeG-nef1, expresses GFP 34 ). The transmitted founder HIV-1 molecular clones CH077.t, CH106.c and REJO.c were provided by B. Hahn 35 . HIV-2 ROD10 , SIV MAC239 , SIV AGMTAN and SIV MND121 have been described [36] [37] [38] [39] [40] , as have the GFPencoding HIV-1-, SIV MAC -, FIV-, EIAV-and MLV-derived lentiviral and retroviral vectors [41] [42] [43] [44] [45] , the HIV-1 CA mutants 46 , and the HIV-1/SIV MAC CA chimaera 47 . Cells and cell culture. Human primary CD4 1 T cells and monocytes were obtained from peripheral blood mononuclear cells (PBMCs) of healthy volunteer donors (approved by the Guy's Research Ethics Committee; Ref 03/02/06). In brief, PBMCs were isolated using LymphoPrep (Axis-Shield) and monocytes were obtained first by positive selection using CD14 MicroBeads (Miltenyi Biotec). CD4 1 T cells were then isolated from the remaining cells using the CD4 1 T cell isolation kit II (Miltenyi Biotec). The purity of isolated cell populations was always .90% as judged by flow cytometric analysis of specific markers (CD4 and CD3 for CD4 1 T cells, or CD14 for monocytes). After 3 h in serum-free Roswell Park Memorial Institute (RPMI) 1640 medium, monocytes were further differentiated into macrophages by culture for 4-6 days in RPMI 1640 supplemented with 10% FBS (Gibco) and 100 ng ml 21 granulocyte-macrophage colony-stimulating factor (R&D Systems). CD4 1 T cells were stimulated for 24 h with 1 mg ml 21 phytohaemagglutinin (PHA, Oxoid) and 50 U ml 21 interleukin-2 (IL-2; BD Pharmingen) before culture in the presence or absence of IFN-a. Human monocytic THP-1 and U937 cells and lymphoid Jurkat, CEM, CEM-SS and HUT78 cells were grown in RPMI 1640 medium, supplemented with 10% FBS. The differentiation of THP-1 and U937 cells (phorbol-12-myristate-13-acetate (PMA)-THP-1 and PMA-U937, respectively) was achieved by 24-h stimulation with 100 ng ml 21 PMA (Sigma-Aldrich). Human glioblastoma U87-MG and 293T cells were maintained in complete DMEM plus 10% FBS. When indicated, IFN-a (universal type 1 IFN, PBL InterferonSource) was added at 500-1,000 U ml 21 for 24 h before RNA extraction, immunoblotting or virus infection.
U87-MG CD4 1 CXCR4 1 (that is, U87-MG cells modified to express HIV-1 receptors) were obtained in one of two ways: (1) for experiments in which viral DNA accumulation was analysed (that is, Fig. 3 ), cells were transduced with a MLV-based retroviral vector containing a CD4-IRES-CXCR4 expression cassette (derived from pMIGR1 (ref. 48 ) by introduction of CD4 as an XhoI-EcoRI fragment and CXCR4 as an NcoI-SalI fragment to replace GFP); (2) for the other experiments (for example, Figs 1b, 2 and 4e ), cells were transduced with a combination of an HIV-1-based lentiviral vector expressing a CD4-IRES-puromycin N-acetyltransferase (hereafter called puromycinR) expression cassette (pRRL. sin.cPPT.CMV/CD4-IRES-puromycinR.WPRE, obtained by replacement of the enhanced GFP (eGFP) cassette in pRRL.sin.cPPT.CMV/eGFP.WPRE by a CD4-IRES-puromycinR BamHI-Sall fragment, using overlapping PCR) and an MLVbased retroviral vector containing a CXCR4-IRES-neomycinR expression cassette (modified from NG/neo by adding CXCR4 as an XhoI-EcoRI fragment 2 ). In the latter case, transduced cells were selected with 1 mg ml 21 puromycin plus 100 mg ml 21 G418.
293T-TetR-KRAB cells (expressing a fusion of the tetracyclin repressor protein, TetR, with a transcriptional repressor domain, the Krüppel-associated box protein, KRAB) were obtained via 293T transduction with an HIV-1-based lentiviral vector expressing a TetR-KRAB-IRES-puromycinR expression cassette (obtained by replacing CD4 from pRRL.sin.cPPT.CMV/CD4-IRES-puromycinR.WPRE with the TetR-KRAB coding sequence, amplified from pptTRKrab 49 ) and selected for a few days with 1 mg ml 21 puromycin. Fresh 293T-TetR-KRAB cells were generated every ,10 days.
U87-MG/LTR-Luc indicator cells were obtained by transducing U87-MG cells with an HIV-1-based lentiviral vector containing the firefly luciferase reporter gene under the control of HIV-1 LTR (pK365, provided by J. Kappes 50 ). These cells mirror the widely used TZM-bl indicator cells 50 and express luciferase in response to expression of HIV and SIV Tat trans-activator proteins. Microarray analysis. In total, 1-2 3 10 6 primary CD4 1 T cells (previously activated with IL-2 and PHA), MDMs, CEM, CEM-SS, Jurkat, U87-MG, HT1080, U937, PMA-U937, THP-1 and PMA-THP-1 cells were collected 24 h after IFN-a treatment, or no treatment. RNA was isolated using the miRNeasy kit with oncolumn DNase treatment (Qiagen). A total of 500 ng RNA was used for complementary RNA probe preparation using the Illumina TotalPrep RNA Amplification Kit (Ambion), according to the manufacturer's instructions. The probes were hybridized on Illumina HT12v4 bead arrays following the manufacturer's standard hybridization and scanning protocols.
Raw signals, detection P values, bead numbers and bead-level standard errors were exported for regular and control probes from GenomeStudio. Data were imported into R using the Bioconductor beadarray and illuminaHumanv4.db packages. Microarray probes annotated by the latter as not or badly mapping to the reference genome were excluded. Data then were background-corrected, quantile-normalized and log 2 -transformed using the limma implementation of the neqc method 51 . Using limma, a factorial linear model (cell type 3 treatment) was fitted to data, and relative array quality weights were computed. The range of the quality weights was small (0.4-1.3), indicating consistent quality across arrays. Probes were tested for significant (F test; false discovery rate (FDR) , 5%) expression above the global median signal in any of the conditions. This test resulted in 21,030 probes being retained for further analysis. Hierarchical clustering of the data showed tight and distinct clusters corresponding to cell type, with no indication of a technical bias or batch effect being present. Using the data for the retained probes, a linear model was fitted, with cell type and treatment being independent (additive) factors. Probes were tested for significant (FDR , 1%) differential expression due to cell type (relative to the CEM lymphoid cell line), and due to treatment (IFN-a treatment versus no treatment). The final list of candidate genes was generated imposing an additional log 2 fold-change effect size threshold of .2 (.4-fold upregulation) on the comparison between MDMs and the CEM cells as well as on the IFN-a treatment versus no treatment contrast, implying an additive effect size of .4 (.16-fold upregulation) on gene expression. EasiLV inducible lentiviral vector system. The arrangement of this vector is diagrammed in Fig. 1a . pEasiLV-MCS (pRRL.sin.cPPT.(7TetOCMV/MCS. IRES.rtTA3-2A-E2-Crimson) antisense .WPRE) was constructed using the following steps: (1) the 7TetOCMV/d2GFP-IRES-rtTA3 tetracycline (Tet)-inducible expression cassette from TREautoR3 (provided by J. Seppen 52 ) was modified by overlapping PCRs to remove the stop codon from the rtTA3 coding sequence and to add, in frame, both the sequence coding the 2A-like peptide from Thosea asigna virus (hereafter called the 2A peptide (NH 2 -GSGEGRGSLLTCGDVEENPGP), which allows the generation of two independent proteins by a co-translational cleavage process 53, 54 ) and the E2-Crimson fluorescent reporter gene; (2) the inducible cassette was further modified to add a synthetic polyadenylation signal (polyA, amplified from pGL4, Promega) upstream of the Tet inducible promoter (to stop any potential on-going transcription) and the BGH polyA (amplified from pcDNA3.1) downstream of the E2-Crimson coding sequence; (3) the entire inducible cassette was inserted into an HIV-1-based lentiviral vector (pRRL.sin.cPPT.CMV/ eGFP.WPRE 41 ) in place of the CMV-eGFP cassette in the antisense orientation, to create pEasiLV (E2-crimson antisense inducible lentiviral vector); and (4) pEasiLV-MCS was created by introducing a multiple cloning site (MCS) containing BamHI, AgeI, PacI, PmeI, Tth111I, SnaBI, XhoI and NsiI restriction sites. Cloning of candidate cDNAs. The candidate cDNAs (refer to Extended Data Table  1 for accession numbers), as well as IFITM3 cDNA (NM_021034), were amplified using the SuperScript III One-Step RT-PCR System with Platinum Taq (Invitrogen) from 20 to 100 ng RNA obtained from IFNa-treated MDMs, except for IFIH1, which was amplified by PCR from pEF_Bos_2xFLAG_MDA5 55 . cDNAs, as well as CD8 and GFP (negative controls), were inserted into pEasiLV-MCS between the BamHI and XhoI sites (or BamHI/NsiI in the case of GBP1). The TRIMCyp cDNA (positive control) was amplified by PCR from pEXNomtRBCC-NotI-huCypA 46 and inserted into pEasiLV-MCS as an AgeI-XhoI fragment.
cDNAs encoding MX1 and MX2 Flag-tagged at their carboxy termini, and the derivative GTPase domain mutants (MX1(K83A)-Flag, MX1(T103A)-Flag and MX2(K131A)-Flag) were inserted into pEasiLV-MCS using standard mutagenesis and cloning techniques. Viral production. To produce EasiLV particles, 293T-TetR-KRAB cells were cotransfected with pEasiLV, p8.91, pptTRKrab 49 and pMD.G at a ratio of 1:1:0.5:0.25, respectively, with Fugene 6 reagent (Promega). The medium was replaced after overnight incubation and viral particles collected at 24 h, filtered and used directly to transduce target cells. After a few hours, the media was replaced and doxycycline added (0.5 mg ml 21 , Sigma-Aldrich) to induce transgene expression. The percentage of E2-Crimson-positive cells was scored by flow cytometry (FACSCalibur, BD Biosciences) after 48 h and was typically .85%.
HIV-1 particles were produced by standard polyethylenimine (PEI) transfection of 293T monolayers. VSV-G-pseudotyped HIV and SIV stocks were prepared by co-transfection using a 3:1 ratio of provirus to pMD.G 56 , the culture medium was changed at ,6 h, and virus containing supernatant collected at ,36 h. Lentiviral and retroviral vector stocks were obtained by PEI-mediated triple transfection of 293T cells with vectors expressing Gag-Pol (p8.91, pFP93, pEV53, pSIV3 1 , p5349 for HIV-1, FIV, EIAV, SIV MAC or MLV, respectively) or HIV-1 vectors with modified CA regions (CA P90A , CA N74D or CA SIV ), vectors expressing miniviral genomes bearing a CMV-eGFP cassette (pRRL.sin.cPPT.CMV/eGFP. WPRE, pGiNW, pSIN6.1CeGFPW, pGAE1.0 or p13077), and pMD.G, at a ratio of 1:1:0.5.
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Viral particles were filtered, and when required (that is, to enable NL4-3/Nef-IRES-Renilla or NL4-3/Nef-IRES-GFP to be used in 96-well format infections), virus containing supernatants were purified by ultracentrifugation through a sucrose cushion (20% w/v; 75 min; 4 uC, 145,370g using a Sorvall Surespin630 rotor), re-suspended in RPMI 1640 medium without serum and stored in aliquots at 280 uC.
Viral particles were normalized according to HIV-1 p24 Gag ELISA (Perkin Elmer), by RT ELISA (Roche Applied Science) and/or by determining their infectious titres on U87-MG cells. The m.o.i. for lentiviral and retroviral vector stocks was determined by infecting a known number of U87-MG cells with standardized amounts of viral particles and evaluating by flow cytometry the percentage of infected cells 2-3 days later. For instance, an m.o.i. of 0.25 equates to the volume of virus necessary to obtain 25% of GFP-expressing U87-MG cells. Lentiviral infection. All infections were initiated using standard conditions, often using a range of viral inocula. For infection with NL4-3/Nef-IRES-Renilla or GFPexpressing lentiviral and retroviral vector, U87-MG CD4 1 CXCR4 1 , U87-MG/ LTR-Luc or 293T cells were plated at 2.5-5 3 10 4 per well in 96-well plates. CEM-SS cells were plated at 2 3 10 5 per well in 96-well plates. When HIV-1 infection was followed by DNA extraction or p24 Gag intracellular staining, U87-MG CD4 1 CXCR4 1 cells were seeded at ,2 3 10 5 cells per well in 24-well plates. When required, cells were treated with IFN-a or reverse transcriptase inhibitors (AZT and 3TC, 10 mM each) for 24 h or at least 15 min, respectively, before viral challenge.
The efficiency of productive infection was analysed after ,48 h by evaluating the percentage of GFP-or p24 Gag -expressing cells using flow cytometry (FACSCalibur, BD Biosciences), or by measuring either firefly or Renilla luciferase activity (Promega). For p24 Gag intracellular staining, the cells were washed in PBS, incubated for 10 min in trypsin to remove surface-associated virion particles, fixed and permeabilized (Intrastain kit, DAKO), and then stained with a p24 Gag -specific antibody (KC57-RD1, Beckman Coulter) 10 . Influenza A virus infection. Wild-type human MX1, MX2, or MX1 GTPase domain mutants T103A and K83A, as well as IFITM3 cDNAs, were subcloned from pEasiLV into pRRL.sin.cPPT.CMV/eGFP-IRES-puromycinR.WPRE in place of GFP using BamHI and XhoI. The corresponding vectors (and the GFP negative control) were transfected into 293T cells (0.4 mg) in 24-well plates using lipofectamine 2000 (Invitrogen) simultaneously with a firefly luciferase minigenome expressing plasmid (pHSPOM1-Firefly, 0.2 mg 57 ) and a Renilla luciferase expression plasmid (T7-Renilla, 0.06 mg). The minigenome plasmid pHSPOM1-Firefly contains the triple mutation 3-5-8 in the 39 noncoding region of the viral promoter that flanks the firefly luciferase reporter gene, yielding increased expression when driven by influenza virus polymerase 58 . At 24 h, cells were infected with influenza A virus A/Victoria/3/75 (H3N2) at an m.o.i. of 2, or mock infected. Activities of firefly and Renilla luciferases were measured 18 h after infection and firefly luciferase signals were normalized to Renilla luciferase signals from mock-infected cells. shRNA-mediated MX2 silencing. Silencing was achieved using a modified version of the HIV-1-based lentiviral vector pAPM (pALPS-Puro-miR-30 59 ). The puromycin-resistance gene was replaced by the hygromycin-resistance gene (hygromycin B phosphotransferase), creating pAHM. DNAs encoding two different MX2-specific microRNA-based shRNAs were inserted as XhoI-EcoRI fragments into pAHM. Primer sequences were designed through the Open Biosystems website facility as follows: shMX2-1, 59-TGCTGTTGACAGTGAGCGCCAAGATGTTCTTTCTAATTGA TAGTGAAGCCACAGATGTATCAATTAGAAAGAACATCTTGTTGCCTAC TGCCTCGGA-39 (target sequence, 59-AAGATGTTCTTTCTAATTG-39); and shMX2-2, 59-TGCTGTTGACAGTGAGCGAGCCAACCAGATCCCATTTATA TAGTGAAGCCACAGATGTATATAAATGGGATCTGGTTGGCGTGCCTAC TGCCTCGGA-39 (target sequence, 59-CCAACCAGATCCCATTTAT-39). These were used as a template PCR with forward and reverse primers: miR-30-XhoI (59-GATGGCTGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-39) and miR-30-EcoRI (59-GTCTAGAGGAATTCCGAGGCAGTAGGCA-39). The pAHM nontargeting shCtrl insert was 59-CTCCCGTGAATTGGAATCC-39. Lentiviral vectors were produced by co-transfection of 293T cell monolayers with p8.91, pMD.G and the pAHM-based vector (at a ratio of 1:0.25:1), and U87-MG CD4 1 CXCR4 1 or THP-1 cells were transduced with filtered supernatant for 6-8 h before media replacement. To achieve good silencing efficiency, cells were challenged 3-4 times with high viral inputs a few days apart and cultured for at least 7 days in the presence of 50 mg ml 21 hygromycin before analysis. Quantification of mRNA expression. In total, 1-2 3 10 6 cells were collected with or without 24-h treatment with IFN-a, and total RNA was isolated using the miRNeasy kit with on-column DNase treatment (Qiagen). cDNA was generated using 500 ng RNA and analysed by qPCR using TaqMan gene expression assays (Applied Biosystems) specific for human MX2 (Hs01550808_m1), ISG15 (Hs00192713_m1), ACTB (Hs99999903_m1) or GAPDH (Hs99999905_m1). Triplicate reactions were run according to the manufacturer's instructions using an ABI Prism model 7900HT sequence detection platform, and the RQ software (Applied Biosystems) was used for subsequent analysis. For relative quantification, samples were normalized for both GAPDH and ACTB mRNA expression. Immunoblot analysis. Cell pellets were lysed in sample buffer (200 mM Tris-HCl, pH 6.8, 5.2% SDS, 20% glycerol, 0.1% bromphenol blue, 5% b-mercaptoethanol), resolved by SDS-PAGE and analysed by immunoblotting using primary antibodies specific for human MX2 (goat N-17, Santa Cruz Biotechnology), Flag (mouse monoclonal M2, Sigma-Aldrich), SAMHD1 (mouse monoclonal 1F9, Abcam), HSP90 (rabbit, Santa Cruz Biotechnology), tubulin (mouse monoclonal DM1A, Sigma-Aldrich) and APOBEC3G 60 , followed by secondary horseradish peroxidase-conjugated anti-goat, anti-mouse or anti-rabbit immunoglobulin antibodies and chemiluminescence (ECL 1 western blotting substrate, Pierce). qPCR analysis of HIV-1 reverse transcription products. In total, 2 3 10 5 U87-MG CD4 1 CXCR4 1 cells per well in 24 well plates were left untransduced, treated with or without IFN-a, or transduced with CD8-or MX2-expressing EasiLV. The cells were then challenged with HIV-1 IIIB (10 ng p24 Gag ) in the presence or absence of reverse transcriptase inhibitors (AZT and 3TC, 10 mM each) for 2 h. The cells were then washed twice, incubated in complete medium (supplemented with 0.5 mg ml 21 doxycycline or reverse transcriptase inhibitors as required) and collected at 2, 6, 24 or 48 h after infection. Total DNA was prepared using the DNeasy kit (Qiagen) and 30 ng of each sample was used for qPCR analysis. First (minus)strand transfer cDNA products were detected using primers that amplify the region between nucleotides 53 and 175 of pIIIB in U3 (U3 forward, 59-TC TACCACACACAAGGCTAC-39 and U3 reverse, 59-CTTCTAACTTCTCTG GCTCAAC-39), with U3 probe (59-FAM-CAGAACTACACACCAGGACCAGG GATCA-TAMRA-39); 2-LTR circular forms were detected using primers that amplify the region between nucleotides 585 (39 terminus of U5) and 102 of pIIIB (59-terminus of U3) (2-LTR forward, 59-GTAACTAGAGATCCCTCAG ACC-39 and 2-LTR reverse, 59-TCCTGGTGTGTAGTTCTGCC-39), with 2-LTR probe (59-FAM-CTACCACACACAAGGCTACTTCCCTGAT-TAMRA-39). Integrated (provirus) DNA was analysed using Alu PCR 61 . In brief, 16 cycles of pre-amplification (15 s at 94 uC, 15 s at 55 uC, 100 s at 68 uC) were conducted with Platinum Taq DNA High Fidelity polymerase (Invitrogen) using 100 nM of genomic Alu forward primer (59-GCCTCCCAAAGTGCTGGGATTACAG-39) and 600 nM of U3 reverse primer in 15 ml; for the first experiment, the pre-amplification step was performed on serial dilutions of all the DNA samples, as well as of a positive control (DNA from IIIB-infected CEM-SS cells), to ensure the linearity of the assay (subsequent experiments only used a dilution series of the control). Linear, one-way amplification was also monitored by performing the pre-amplification PCR with the U3 reverse primer alone, resulting in background levels of amplification or no amplification. Second-round qPCR was performed on preamplification products using the U3 forward and U3 reverse primers with the U3 probe. qPCR reactions were performed in triplicate, in universal PCR master mix using 900 nM of each primer and 250 nM probe. After 10 min at 95 uC, reactions were cycled through 15 s at 95 uC followed by 1 min at 60 uC for 40 repeats. pIIIB or pTOPO-2-LTR (contains a 2-LTR circle junction amplified from HIV-1 IIIBinfected CEM-SS cell DNA using primers oHC64 (59-TAACTAGGGAACCCA CTGC-39) and U3 reverse, and cloned into pPCR-Blunt II-TOPO) were diluted in 20 ng ml 21 salmon sperm DNA to create dilution standards that were used to calculate relative cDNA copy numbers and confirm the linearity of all assays.
U3 primers were used for these Alu PCR assays because the corresponding sequences are absent from pEasiLV, ensuring that nascent cDNA rather than vector sequences were amplified.
